Glioblastoma: State of the Art and Future Perspectives
Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, r...
Saved in:
Other Authors: | , |
---|---|
Format: | Electronic Book Chapter |
Language: | English |
Published: |
Basel, Switzerland
MDPI - Multidisciplinary Digital Publishing Institute
2020
|
Subjects: | |
Online Access: | DOAB: download the publication DOAB: description of the publication |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000naaaa2200000uu 4500 | ||
---|---|---|---|
001 | doab_20_500_12854_68811 | ||
005 | 20210501 | ||
003 | oapen | ||
006 | m o d | ||
007 | cr|mn|---annan | ||
008 | 20210501s2020 xx |||||o ||| 0|eng d | ||
020 | |a books978-3-03928-261-6 | ||
020 | |a 9783039282609 | ||
020 | |a 9783039282616 | ||
040 | |a oapen |c oapen | ||
024 | 7 | |a 10.3390/books978-3-03928-261-6 |c doi | |
041 | 0 | |a eng | |
042 | |a dc | ||
072 | 7 | |a GP |2 bicssc | |
072 | 7 | |a PS |2 bicssc | |
100 | 1 | |a Tabatabai, Ghazaleh |4 edt | |
700 | 1 | |a Wakimoto, Hiroaki |4 edt | |
700 | 1 | |a Tabatabai, Ghazaleh |4 oth | |
700 | 1 | |a Wakimoto, Hiroaki |4 oth | |
245 | 1 | 0 | |a Glioblastoma: State of the Art and Future Perspectives |
260 | |a Basel, Switzerland |b MDPI - Multidisciplinary Digital Publishing Institute |c 2020 | ||
300 | |a 1 electronic resource (784 p.) | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
506 | 0 | |a Open Access |2 star |f Unrestricted online access | |
520 | |a Glioblastoma is an aggressive incurable primary tumor of the central nervous system. Median overall survival is in the range of 1.5 years even in selected clinical trials populations. Many features contribute to this therapeutic challenge including high intratumoral and intertumoral heterogeneity, resistance to therapy, migration and invasion, immunosuppression. With the access of novel highthroughput technologies, significant progress has been made to understand molecular and immunological signatures underlying the pathology of glioblastoma. Clinical trial designs have shifted from investigating broad "one-for-all" treatment approaches to precision oncology designs. The collection of contributions in this book aim at providing researchers and clinicians an update on different aspects of glioblastoma, i.e. progress in basic, preclinical and clinical research. | ||
540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |4 https://creativecommons.org/licenses/by/4.0/ | ||
546 | |a English | ||
650 | 7 | |a Research & information: general |2 bicssc | |
650 | 7 | |a Biology, life sciences |2 bicssc | |
856 | 4 | 0 | |a www.oapen.org |u https://mdpi.com/books/pdfview/book/2577 |7 0 |z DOAB: download the publication |
856 | 4 | 0 | |a www.oapen.org |u https://directory.doabooks.org/handle/20.500.12854/68811 |7 0 |z DOAB: description of the publication |